These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Kumar A; Casulo C; Yahalom J; Schöder H; Barr PM; Caron P; Chiu A; Constine LS; Drullinsky P; Friedberg JW; Gerecitano JF; Hamilton A; Hamlin PA; Horwitz SM; Jacob AG; Matasar MJ; McArthur GN; McCall SJ; Moskowitz AJ; Noy A; Palomba ML; Portlock CS; Straus DJ; VanderEls N; Verwys SL; Yang J; Younes A; Zelenetz AD; Zhang Z; Moskowitz CH Blood; 2016 Sep; 128(11):1458-64. PubMed ID: 27458003 [TBL] [Abstract][Full Text] [Related]
12. Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial. Fornecker LM; Lazarovici J; Aurer I; Casasnovas RO; Gac AC; Bonnet C; Bouabdallah K; Feugier P; Specht L; Molina L; Touati M; Borel C; Stamatoullas A; Nicolas-Virelizier E; Pascal L; Lugtenburg P; Di Renzo N; Vander Borght T; Traverse-Glehen A; Dartigues P; Hutchings M; Versari A; Meignan M; Federico M; André M; J Clin Oncol; 2023 Jan; 41(2):327-335. PubMed ID: 35867960 [TBL] [Abstract][Full Text] [Related]
13. [Brentuximab Vedotin, Doxorubicin, Vinblastine, Dacarbazine(A+AVD)Therapy for Classical Hodgkin Lymphoma- A Single-Institution Experience]. Kobayashi M; Yokoyama E; Izumiyama K; Mori A; Saito M; Morioka M; Kondo T Gan To Kagaku Ryoho; 2023 Sep; 50(9):979-983. PubMed ID: 37800293 [TBL] [Abstract][Full Text] [Related]
14. Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma. Evens AM; Advani RH; Helenowski IB; Fanale M; Smith SM; Jovanovic BD; Bociek GR; Klein AK; Winter JN; Gordon LI; Hamlin PA J Clin Oncol; 2018 Oct; 36(30):3015-3022. PubMed ID: 30179569 [TBL] [Abstract][Full Text] [Related]
15. An evaluation of brentuximab vedotin as a treatment option for stage III/IV Hodgkin lymphoma. Choi Y; Diefenbach CS Expert Rev Hematol; 2019 Oct; 12(10):801-808. PubMed ID: 31432732 [No Abstract] [Full Text] [Related]
16. Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial. Rubinstein PG; Moore PC; Bimali M; Lee JY; Rudek MA; Chadburn A; Ratner L; Henry DH; Cesarman E; DeMarco CE; Costagliola D; Taoufik Y; Ramos JC; Sharon E; Reid EG; Ambinder RF; Mitsuyasu R; Mounier N; Besson C; Noy A; ; Lancet Haematol; 2023 Aug; 10(8):e624-e632. PubMed ID: 37532416 [TBL] [Abstract][Full Text] [Related]
17. Methotrexate-associated Hodgkin Lymphoma in a Patient with Rheumatoid Arthritis Successfully Treated with Brentuximab Vedotin in Combination with Doxorubicin, Vinblastine, and Dacarbazine (BV+AVD). Sekiguchi Y; Iizuka H; Takizawa H; Sugimoto K; Sakajiri S; Inano T; Fukuda Y; Shirane S; Hamano Y; Tomita S; Izumi H; Okubo M; Nakamura N; Sawada T; Sekiguchi N; Noguchi M Intern Med; 2020 Sep; 59(17):2165-2171. PubMed ID: 32461524 [TBL] [Abstract][Full Text] [Related]
18. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial. Cheson BD; Bartlett NL; LaPlant B; Lee HJ; Advani RJ; Christian B; Diefenbach CS; Feldman TA; Ansell SM Lancet Haematol; 2020 Nov; 7(11):e808-e815. PubMed ID: 33010817 [TBL] [Abstract][Full Text] [Related]
19. ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma. Park SI; Shea TC; Olajide O; Reddy NM; Budde LE; Ghosh N; Deal AM; Noe JF; Ansell SM Blood Adv; 2020 Jun; 4(11):2548-2555. PubMed ID: 32516414 [TBL] [Abstract][Full Text] [Related]
20. Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study. Evens AM; Connors JM; Younes A; Ansell SM; Kim WS; Radford J; Feldman T; Tuscano J; Savage KJ; Oki Y; Grigg A; Pocock C; Dlugosz-Danecka M; Fenton K; Forero-Torres A; Liu R; Jolin H; Gautam A; Gallamini A Haematologica; 2022 May; 107(5):1086-1094. PubMed ID: 34162178 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]